Low-Dose Finasteride Has Little Impact on PSA Levels of Older Men at Risk for Prostate Cancer: Presented at AUA
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Low-Dose Finasteride Has Little Impact on PSA Levels of Older Men at Risk for Prostate Cancer: Presented at AUA

By Karen Shoffner

CHICAGO -- April 28, 2009 -- A study observing the impact of low-dose finasteride on the prostate specific antigen (PSA) levels in older men at risk of developing prostate cancer was varied and "unexpectedly small," stated researchers here on April 26 at the 2009 American Urological Association (AUA) Annual Meeting.

Kazuto Ito, MD, Department of Urology, Gunma University School of Medicine, Maebashi, Japan, and colleagues evaluated the impact of finasteride 1 mg/day on serum PSA levels in men with androgenic alopecia who participated in population-based screening for prostate cancer.

A total of 37,645 men were screened, and their PSA levels were measured. In addition, men answered a questionnaire asking if they were using low-dose finasteride for the treatment of androgenic alopecia.

Of the several thousand men screened, 88 were taking finasteride. The proportion of men taking finasteride was highest, at 0.43%, in men aged 50 to 59 years. Of the 88 men, 66 had undergone PSA screening 1 year before the last screening.

Of the 66 men, 16 had decreased PSA levels of more than 20% between the most recent screening and the last screening. PSA levels decreased less than 20% in 17 of the men, while 29 had increased levels.

The mean percent changes in the men between the most recent screening and the last screening ranged from 1.9% to -10.1% with the most recent PSA levels ranging from 0.0 to 4.0 ng/mL to 2.1 to 4.0 ng/mL.

According to the researchers, the findings suggest that aging and existing benign prostatic hyperplasia (BPH) may result in small changes in serum PSA levels in about 75% of men taking low-dose finasteride.

"The relationship between aging, the presence or absence of BPH, and the impact of taking low-dose finasteride on PSA reduction should be investigated," they concluded.

[Presentation title: Impact of Low Dose Finasteride for the Treatment of Androgenic Alopecia on Serum Prostate Specific Antigen (PSA) Levels in Men Participated in Population-Based Screening for Prostate Cancer. Abstract 591]

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities